Higher carfilzomib dose induced durable response in multiple myeloma

  • July 29, 2014

A higher dose of carfilzomib induced a high overall response rate and “a remarkable duration of response” in patients with relapsed or refractory multiple myeloma, according to results of a phase 2 study.

The higher-dose regimen also demonstrated a manageable toxicity profile, although grade 3 and grade 4 adverse events related to treatment included heart failure and hypertension.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More»
More»
More»
More»
More »
  • Financial Planning
  • RUDZINSKI COLUMN
  • Advice for physicians
  • Be aware of important 2014 IRA updates. Analysis by Certified Financial Planner Ken Rudzinski.
More »
HemOnc Today